T2 Biosystems Plans Own Laboratory to Produce Lyme Disease Diagnostic Kits -- Share Down
T2 Biosystems (TTOO) shares were down nearly 6% in recent trading Monday as the company disclosed plans to build or buy its own laboratory to produce the T2Lyme diagnostic kit.
The company previously had plans to launch the product through a partnership.
T2Lyme is a direct-from-blood molecular diagnostic test for the early detection of Borrelia burgdorferi, the bacterium that causes Lyme disease in the US, according to T2 Biosystems.
Price: 2.78, Change: -0.17, Percent Change: -5.76
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.